dasabuvir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals RNA polymerase (NS5B) inhibitors 4914 1132935-63-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasabuvir sodium monohydrate
  • dasabuvir
  • dasabuvir sodium
  • exviera
  • ABT-333
Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. In a biochemical assay, dasabuvir inhibited a panel of genotype 1a and 1b NS5B polymerases. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor.
  • Molecular weight: 493.58
  • Formula: C26H27N3O5S
  • CLOGP: 4.07
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 104.81
  • ALOGS: -5.79
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 2.13 L/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2014 EMA AbbVie Ltd
Dec. 19, 2014 FDA ABBVIE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 572.47 46.24 119 1051 5389 2351526
Hyperbilirubinaemia 466.45 46.24 82 1088 1467 2355448
Hepatic failure 414.90 46.24 92 1078 5597 2351318
Ascites 377.40 46.24 85 1085 5535 2351380
Asthenia 331.27 46.24 122 1048 46804 2310111
Blood bilirubin increased 321.68 46.24 74 1096 5271 2351644
Vomiting 308.09 46.24 130 1040 71472 2285443
Anaemia 246.41 46.24 91 1079 34701 2322214
Nausea 231.82 46.24 123 1047 112066 2244849
Hepatic cirrhosis 220.91 46.24 47 1123 2306 2354609
Renal impairment 205.60 46.24 59 1111 10033 2346882
Hepatocellular carcinoma 199.95 46.24 35 1135 597 2356318
Hepatic encephalopathy 190.75 46.24 39 1131 1568 2355347
Pruritus 140.33 46.24 65 1105 43275 2313640
Fatigue 124.80 46.24 75 1095 84798 2272117
General physical health deterioration 110.51 46.24 40 1130 14099 2342816
Diarrhoea 107.79 46.24 68 1102 83496 2273419
Malaise 105.12 46.24 58 1112 55527 2301388
Oedema peripheral 103.53 46.24 44 1126 23719 2333196
Encephalopathy 103.09 46.24 29 1141 4532 2352383
Decreased appetite 98.42 46.24 45 1125 28846 2328069
Hyponatraemia 90.43 46.24 34 1136 13291 2343624
Renal failure 88.55 46.24 36 1134 17313 2339602
Acute kidney injury 87.01 46.24 41 1129 28081 2328834
Abdominal pain upper 80.15 46.24 36 1134 22064 2334851
Dyspnoea 79.25 46.24 55 1115 78678 2278237
Child-Pugh-Turcotte score increased 75.54 46.24 9 1161 2 2356913
Acute hepatic failure 74.48 46.24 20 1150 2622 2354293
Varices oesophageal 72.52 46.24 14 1156 413 2356502
Hepatorenal syndrome 71.00 46.24 13 1157 286 2356629
Hyperkalaemia 66.59 46.24 22 1148 5871 2351044
Abdominal pain 65.06 46.24 36 1134 34338 2322577
Cardiac failure 64.74 46.24 26 1144 12068 2344847
Cardio-respiratory arrest 64.39 46.24 24 1146 9122 2347793
Yellow skin 64.02 46.24 13 1157 499 2356416
Headache 62.39 46.24 48 1122 80131 2276784
Upper gastrointestinal haemorrhage 59.85 46.24 16 1154 2058 2354857
Melaena 57.30 46.24 18 1152 4088 2352827
Urinary tract infection 55.64 46.24 31 1139 29911 2327004
Dyspepsia 55.57 46.24 22 1148 9822 2347093
Atrial fibrillation 54.88 46.24 24 1146 13744 2343171
Haemoglobin decreased 54.59 46.24 26 1144 18125 2338790
Dizziness 54.23 46.24 39 1131 58626 2298289
Hepatic cancer 53.18 46.24 12 1158 763 2356152
Pyrexia 52.61 46.24 37 1133 53671 2303244
Portal vein thrombosis 51.89 46.24 11 1159 522 2356393
Death 51.04 46.24 43 1127 81425 2275490
Chromaturia 50.95 46.24 15 1155 2738 2354177
Pneumonia 50.70 46.24 35 1135 49261 2307654
Somnolence 48.25 46.24 26 1144 23459 2333456
Alanine aminotransferase increased 48.05 46.24 22 1148 14010 2342905

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal impairment 421.96 48.28 121 1096 12193 1733371
Ascites 356.78 48.28 90 1127 5496 1740068
Jaundice 244.52 48.28 68 1149 5994 1739570
Hyperbilirubinaemia 244.50 48.28 56 1161 2231 1743333
Hepatocellular carcinoma 243.80 48.28 56 1161 2260 1743304
Blood bilirubin increased 220.14 48.28 63 1154 6147 1739417
Hepatic failure 209.70 48.28 60 1157 5843 1739721
Hepatic cirrhosis 174.84 48.28 44 1173 2609 1742955
Hepatic encephalopathy 165.95 48.28 41 1176 2251 1743313
Anaemia 145.71 48.28 70 1147 29387 1716177
Asthenia 143.65 48.28 73 1144 34597 1710967
Fatigue 112.49 48.28 71 1146 50710 1694854
Abdominal pain 84.93 48.28 44 1173 21446 1724118
Diarrhoea 68.99 48.28 54 1163 53798 1691766
Encephalopathy 68.54 48.28 24 1193 4428 1741136
Nausea 64.81 48.28 51 1166 51145 1694419
Dyspnoea 61.91 48.28 50 1167 52009 1693555
Decreased appetite 61.69 48.28 37 1180 23834 1721730
Vomiting 61.40 48.28 44 1173 38271 1707293
Oesophageal varices haemorrhage 60.85 48.28 14 1203 559 1745005
Gastroenteritis 59.70 48.28 18 1199 2066 1743498
Renal failure 56.86 48.28 33 1184 19984 1725580
Alanine aminotransferase increased 56.74 48.28 28 1189 12250 1733314
Oedema peripheral 50.50 48.28 28 1189 15522 1730042

Pharmacologic Action:

SourceCodeDescription
ATC J05AP09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
CHEBI has role CHEBI:36044 antiviral drug
FDA EPC N0000191257 Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
FDA MoA N0000191258 RNA Replicase Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.38 acidic
pKa2 9.01 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10201584 May 17, 2032 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 10201542 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9629841 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10105365 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9333204 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9744170 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D10553 KEGG_DRUG
C3883272 UMLSCUI
DE54EQW8T1 UNII
9741 INN_ID
1456607-55-8 SECONDARY_CAS_RN
DB09183 DRUGBANK_ID
CHEBI:85182 CHEBI
C588260 MESH_SUPPLEMENTAL_RECORD_UI
CHEMBL3137312 ChEMBL_ID
CHEMBL3544985 ChEMBL_ID
56640146 PUBCHEM_CID
714105004 SNOMEDCT_US
1597381 RXNORM
015829 NDDF
4034028 VANDF
30778 MMSL
d08322 MMSL
714104000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Viekira Pak HUMAN PRESCRIPTION DRUG LABEL 4 0074-3093 KIT 250 mg None NDA 19 sections